Developer docs
API playgroundTry for free, no card

Search company profiles

Intocell

Full company profile

uuid0002f4c

Namestring
Intocell
Legal namestring
주식회사 인투셀
Websiteurl
intocell.com
Company typeenum
Public
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDaejeon, South Korea
HQ citystring
Daejeon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody drug conjugates, ADC linker technology, payload modification platform, oncology pipeline licensing, camptothecin payload development
Industry1 code
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
ADC Platform Technology / Oncology Bioconjugates
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Platform Technology Licensing (Non-exclusive)
TypeLicensing Royalties
Description

IntoCell licenses its OHPAS linker and PMT technologies on a non-exclusive basis to multiple pharmaceutical and biotech companies simultaneously. Revenue consists of upfront fees upon signing MTA/option agreements, target selection fees, potential development/regulatory/commercial milestone payments, and royalties on net sales upon successful commercialization.

intocell.com
2Co-development and Research Collaboration
TypeProfessional Services
Description

Joint research agreements with partners (e.g., Samsung Bioepis, ADC Therapeutics) where IntoCell provides linker and drug technologies while partners contribute development and manufacturing capabilities. Revenue from research service fees and milestone achievements.

intocell.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Pricing details1 tier
1Non-exclusive platform technology licensing with upfront, milestone, and royalty components
ModelOtherBilling cadenceMulti-year contract
Notes

Upfront fees for MTA/option agreements, target selection fees, development/regulatory milestones, and royalties on net sales. Royalty Stacking clause included in global licensing contracts.

intocell.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Intocell develops and licenses proprietary Antibody-Drug Conjugate (ADC) linker-payload platform technologies—centered on the OHPAS™ linker, PMT™ payload modification technology, and Nexatecans™ camptothecin payloads—offered to pharmaceutical and biotech partners on a non-exclusive basis with upfront fees, milestones, and royalties. The company also advances a proprietary pipeline of ADC candidates (lead asset ITC-6146RO targeting B7-H3) and collaborates with CRDMO partners to integrate its drug-linker technologies into end-to-end ADC development services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Normal cell drug uptake reduced ~172x; selectivity increased ~115x with PMT technology vs conventional ADC payloads
+3 more records
Product overview1 text field

IntoCell operates as an ADC (Antibody-Drug Conjugate) platform technology company specializing in drug-linker technologies and proprietary payloads for targeted cancer therapy. Its core product portfolio consists of three integrated platform technologies: (1) the OHPASTM Linker — a proprietary self-immolative linker compatible with both phenolic and non-phenolic drug payloads; (2) PMTTM (Payload Modification Technology) — which enhances ADC selectivity by minimizing off-target normal cell uptake; and (3) NexatecansTM — a proprietary class of phenol-function camptothecin (Topo1 inhibitor) payloads. These platforms are offered together as a linker-toxin library for screening and fast preclinical candidate delivery. IntoCell also advances proprietary pipeline candidates including ITC-6146RO (B7-H3 ADC) and additional programs targeting Trop2, HER2, HER3, PSMA, 5T4, and DLL3. The company generates revenue primarily through non-exclusive technology licensing of its platforms to biotech and pharmaceutical partners, and through co-development agreements.

Product and service6 records
1OHPAS™ Linker Platform Technology
CategoryPlatform / Core Technology
Description

A proprietary self-immolative linker platform based on Ortho-Hydroxy Protected Aryl Sulfate chemistry enabling stable conjugation and selective release of both phenolic and non-phenolic payloads in antibody-drug conjugates. Stable in blood circulation but releases drug payload upon specific triggers (lysosomal enzymes, pH, light) inside target cells, licensed to pharmaceutical and biotech partners for ADC development.

2PMT™ (Payload Modification Technology)
CategoryPlatform / Core Technology
Description

A platform technology that incorporates temporary modifying groups into traditional drug payloads, reducing non-selective uptake by normal cells while increasing selectivity and improving therapeutic index of ADCs. Licensed as part of IntoCell's linker-payload technology offering to pharma and biotech partners.

3Nexatecans™ Payload Class
CategoryPayload / Drug Candidate
Description

A class of proprietary phenol-function camptothecin (Topo1 inhibitor) payloads developed for use with the OHPAS linker in ADC programs. Designed as an alternative to DXd in ENHERTU with preclinical data showing 2-3x superior efficacy and approximately 5x improved therapeutic index, licensed to ADC developers.

4OHPAS Linker-Toxin Library
CategoryResearch Tool / Platform Component
Description

A library of OHPAS linkers conjugated to toxins with different mechanisms of action, designed to enable rapid screening and selection of optimal drug-linker combinations for novel ADC programs and shorten preclinical candidate identification timelines.

5ITC-6146RO (B7-H3 ADC)
CategoryPipeline Candidate / Drug Product
Description

Lead proprietary ADC candidate targeting B7-H3 using OHPAS linker with duocarmycin-class payload, demonstrating strong and long-lived potency in murine xenograft and PDX models with excellent safety profile. Phase 1 clinical trial approved by MFDS in November 2025.

6Proprietary ADC Pipeline Program Set
CategoryPipeline Candidate
Description

Additional proprietary ADC candidates in pre-clinical development targeting Trop2, HER2 (ISAC and standard ADC formats), HER3, DLL3, PSMA, and 5T4, leveraging IntoCell's OHPAS linker and payload modification platform.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-23
Description

IntoCell signed a technology transfer agreement with ABL Bio for next-generation ADC development. The agreement covered applying IntoCell's platform technologies to ABL Bio's mono- and bispecific antibody-based ADC development. This partnership was subsequently terminated in July 2025 due to a patent dispute over one Nexatecan compound. IntoCell stated it retains 30+ other Nexatecan variants and the OHPAS linker patent is unaffected.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-02
Description

WuXi XDC (stock: 2268.HK), a leading global CRDMO focused on ADC and bioconjugates, entered a comprehensive partnership with IntoCell. IntoCell provides proprietary drug-linker technologies using OHPAS Linker and Nexatecans; WuXi XDC provides fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services. This synergy enables clients to accelerate PCC selection, develop next-generation ADCs, and expedite CMC development. The partnership was announced January 2, 2024.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-05
Description

Samsung Bioepis and IntoCell signed a joint research agreement for the development and validation of ADC candidate materials. IntoCell provides its unique linker and drug technologies; Samsung Bioepis manufactures up to 5 anticancer target ADC materials and evaluates their characteristics. Neither party disclosed contract terms. Samsung Bioepis intends to verify IntoCell's ADC technology competitiveness through animal experiments before discussing detailed development and licensing options. This was Samsung Bioepis' first domestic R&D partnership for ADC development.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-01-04
Description

IntoCell signed a Material Transfer Agreement (MTA) with option to license with ADC Therapeutics (NYSE: ADCT), a commercial-stage Swiss biotech. IntoCell provides proprietary drug-linkers using its OHPAS system and PMT technology. ADC Therapeutics conjugates its own antibodies with IntoCell's drug-linkers for in vitro, in vivo, and toxicology experiments. Upon successful evaluation, ADC Therapeutics has the option to license the technology for up to 6 targets for global development and commercialization. IntoCell retains all global rights beyond reserved targets and receives signing fees, target selection fees, milestone payments, and royalties. The collaboration was facilitated by PharmaVentures Ltd.

5AbStudio
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-10-14
Description

IntoCell and AbStudio entered a research collaboration agreement for ADC development, applying IntoCell's linker-toxin technologies with AbStudio's antibody platforms.

intocell.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-07-13
Description

Cellectar expanded its ongoing collaboration with IntoCell, applying OHPAS linker technology to PDC (Peptide Drug Conjugate) development.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

US clinical-stage biotech developing ADCs and antibody-based therapeutics. Comparable as an emerging ADC developer leveraging proprietary payload and conjugation technologies, though with more emphasis on wholly-owned candidates than platform licensing.

TypeBroad incumbent
Description

Global pharmaceutical leader whose DXd platform underpins ENHERTU and a deep ADC pipeline. IntoCell's Nexatecans are explicitly positioned as DXd alternatives, making Daiichi Sankyo the benchmark incumbent for ADC linker-payload technology.

TypeDirect peer
Description

German biopharma developing proprietary ADC platform (ATAC technology) with proprietary linker chemistry and payloads (amanitin). Direct competitor in the differentiated ADC linker-payload space, also pursuing out-licensing to biopharma partners.

TypeDirect peer
Description

US clinical-stage biotech developing differentiated ADC platforms (Dolasynthen, Immunosynthen) with novel linker-payload systems. Directly comparable as an ADC platform company pursuing licensing and co-development deals with biopharma partners.

TypeEmerging player
Description

US clinical-stage ADC developer with proprietary linker-payload technology and pipeline of wholly-owned ADC candidates. Comparable as an emerging ADC platform company focused on differentiated conjugation chemistry.

TypeOthers
Description

Hong Kong-listed global CRDMO focused on ADCs and bioconjugates, and a IntoCell partner (Jan 2024). Listed here as a strategic enabler/distributor that integrates IntoCell's drug-linker technology into its service platform, rather than a direct technology competitor.

TypeDirect peer
Description

German biotech developing proprietary ADC linker and payload technologies (P5 conjugation, Tub-tag) for therapeutic applications. Direct peer as an ADC platform company focused on linker chemistry innovation and licensing.

TypeDirect peer
Description

KOSDAQ-listed Korean ADC platform company where IntoCell's founder Tae-Kyo Park was previously co-founder and CTO. Both develop proprietary ADC linker-payload technologies for out-licensing and co-development, making them the most directly comparable peer in geography, business model, and technology focus.

TypeEmerging player
Description

US clinical-stage biotech developing ISAC (Immune-Stimulating Antibody Conjugate) platform combining linker-payload technology with immune agonism. Comparable as a differentiated ADC platform company with proprietary linker chemistry for targeted oncology therapeutics.

TypeRegional player
Description

China-based biotech developing site-specific ADC conjugation technologies and proprietary payloads for global biopharma partners. Comparable as an Asia-based ADC linker-payload platform company, with geographic overlap in APAC rather than direct global head-to-head competition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Intocell

ADC Platform Technology / Oncology Bioconjugatesintocell.com

Intocell firmographics

Firmographics
Name
Intocell
Legal name
주식회사 인투셀
Website
https://intocell.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Intocell industry classification

Industry
Product category
ADC Platform Technology / Oncology Bioconjugates
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody drug conjugates
  • ADC linker technology
  • Payload modification platform
  • Oncology pipeline licensing
  • Camptothecin payload development

Where Intocell is headquartered

Location

Headquarters

HQ city
Daejeon
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

Intocell business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. Platform Technology Licensing (Non-exclusive): IntoCell licenses its OHPAS linker and PMT technologies on a non-exclusive basis to multiple pharmaceutical and biotech companies simultaneously. Revenue consists of upfront fees upon signing MTA/option agreements, target selection fees, potential development/regulatory/commercial milestone payments, and royalties on net sales upon successful commercialization.
  2. Co-development and Research Collaboration: Joint research agreements with partners (e.g., Samsung Bioepis, ADC Therapeutics) where IntoCell provides linker and drug technologies while partners contribute development and manufacturing capabilities. Revenue from research service fees and milestone achievements.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractNon-exclusive platform technology licensing with upfront, milestone, and royalty components

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Intocell product offering

Product offering

Core offering

Intocell develops and licenses proprietary Antibody-Drug Conjugate (ADC) linker-payload platform technologies—centered on the OHPAS™ linker, PMT™ payload modification technology, and Nexatecans™ camptothecin payloads—offered to pharmaceutical and biotech partners on a non-exclusive basis with upfront fees, milestones, and royalties. The company also advances a proprietary pipeline of ADC candidates (lead asset ITC-6146RO targeting B7-H3) and collaborates with CRDMO partners to integrate its drug-linker technologies into end-to-end ADC development services.

Product overview

IntoCell operates as an ADC (Antibody-Drug Conjugate) platform technology company specializing in drug-linker technologies and proprietary payloads for targeted cancer therapy. Its core product portfolio consists of three integrated platform technologies: (1) the OHPASTM Linker — a proprietary self-immolative linker compatible with both phenolic and non-phenolic drug payloads; (2) PMTTM (Payload Modification Technology) — which enhances ADC selectivity by minimizing off-target normal cell uptake; and (3) NexatecansTM — a proprietary class of phenol-function camptothecin (Topo1 inhibitor) payloads. These platforms are offered together as a linker-toxin library for screening and fast preclinical candidate delivery. IntoCell also advances proprietary pipeline candidates including ITC-6146RO (B7-H3 ADC) and additional programs targeting Trop2, HER2, HER3, PSMA, 5T4, and DLL3. The company generates revenue primarily through non-exclusive technology licensing of its platforms to biotech and pharmaceutical partners, and through co-development agreements.

Differentiator

Problem solved

Functional benefit

Products and services

  • OHPAS™ Linker Platform Technology A proprietary self-immolative linker platform based on Ortho-Hydroxy Protected Aryl Sulfate chemistry enabling stable conjugation and selective release of both phenolic and non-phenolic payloads in antibody-drug conjugates. Stable in blood circulation but releases drug payload upon specific triggers (lysosomal enzymes, pH, light) inside target cells, licensed to pharmaceutical and biotech partners for ADC development.
  • PMT™ (Payload Modification Technology) A platform technology that incorporates temporary modifying groups into traditional drug payloads, reducing non-selective uptake by normal cells while increasing selectivity and improving therapeutic index of ADCs. Licensed as part of IntoCell's linker-payload technology offering to pharma and biotech partners.
  • Nexatecans™ Payload Class A class of proprietary phenol-function camptothecin (Topo1 inhibitor) payloads developed for use with the OHPAS linker in ADC programs. Designed as an alternative to DXd in ENHERTU with preclinical data showing 2-3x superior efficacy and approximately 5x improved therapeutic index, licensed to ADC developers.
  • OHPAS Linker-Toxin Library A library of OHPAS linkers conjugated to toxins with different mechanisms of action, designed to enable rapid screening and selection of optimal drug-linker combinations for novel ADC programs and shorten preclinical candidate identification timelines.
  • ITC-6146RO (B7-H3 ADC) Lead proprietary ADC candidate targeting B7-H3 using OHPAS linker with duocarmycin-class payload, demonstrating strong and long-lived potency in murine xenograft and PDX models with excellent safety profile. Phase 1 clinical trial approved by MFDS in November 2025.
  • Proprietary ADC Pipeline Program Set Additional proprietary ADC candidates in pre-clinical development targeting Trop2, HER2 (ISAC and standard ADC formats), HER3, DLL3, PSMA, and 5T4, leveraging IntoCell's OHPAS linker and payload modification platform.

Quantifiable outcome

  • Normal cell drug uptake reduced ~172x; selectivity increased ~115x with PMT technology vs conventional ADC payloads
  • +3 more outcomes

Companies that use Intocell

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Intocell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Intocell partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • ABL BiominorStrategic or Co-development Partner · 23 October 2024IntoCell signed a technology transfer agreement with ABL Bio for next-generation ADC development. The agreement covered applying IntoCell's platform technologies to ABL Bio's mono- and bispecific antibody-based ADC development. This partnership was subsequently terminated in July 2025 due to a patent dispute over one Nexatecan compound. IntoCell stated it retains 30+ other Nexatecan variants and the OHPAS linker patent is unaffected.
  • WuXi XDCcoreTechnology or Integration · 2 January 2024WuXi XDC (stock: 2268.HK), a leading global CRDMO focused on ADC and bioconjugates, entered a comprehensive partnership with IntoCell. IntoCell provides proprietary drug-linker technologies using OHPAS Linker and Nexatecans; WuXi XDC provides fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services. This synergy enables clients to accelerate PCC selection, develop next-generation ADCs, and expedite CMC development. The partnership was announced January 2, 2024.
  • Samsung BioepiscoreStrategic or Co-development Partner · 5 December 2023Samsung Bioepis and IntoCell signed a joint research agreement for the development and validation of ADC candidate materials. IntoCell provides its unique linker and drug technologies; Samsung Bioepis manufactures up to 5 anticancer target ADC materials and evaluates their characteristics. Neither party disclosed contract terms. Samsung Bioepis intends to verify IntoCell's ADC technology competitiveness through animal experiments before discussing detailed development and licensing options. This was Samsung Bioepis' first domestic R&D partnership for ADC development.
  • ADC TherapeuticscoreTechnology or Integration · 4 January 2023IntoCell signed a Material Transfer Agreement (MTA) with option to license with ADC Therapeutics (NYSE: ADCT), a commercial-stage Swiss biotech. IntoCell provides proprietary drug-linkers using its OHPAS system and PMT technology. ADC Therapeutics conjugates its own antibodies with IntoCell's drug-linkers for in vitro, in vivo, and toxicology experiments. Upon successful evaluation, ADC Therapeutics has the option to license the technology for up to 6 targets for global development and commercialization. IntoCell retains all global rights beyond reserved targets and receives signing fees, target selection fees, milestone payments, and royalties. The collaboration was facilitated by PharmaVentures Ltd.
  • AbStudiominorStrategic or Co-development Partner · 14 October 2021IntoCell and AbStudio entered a research collaboration agreement for ADC development, applying IntoCell's linker-toxin technologies with AbStudio's antibody platforms.
  • Cellectar BiosciencesminorStrategic or Co-development Partner · 13 July 2021Cellectar expanded its ongoing collaboration with IntoCell, applying OHPAS linker technology to PDC (Peptide Drug Conjugate) development.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Intocell competitors and assessment

Company assessment

Emerging players

  • Pyxis Oncology: US clinical-stage biotech developing ADCs and antibody-based therapeutics. Comparable as an emerging ADC developer leveraging proprietary payload and conjugation technologies, though with more emphasis on wholly-owned candidates than platform licensing.
  • ProfoundBio: US clinical-stage ADC developer with proprietary linker-payload technology and pipeline of wholly-owned ADC candidates. Comparable as an emerging ADC platform company focused on differentiated conjugation chemistry.
  • Bolt Biotherapeutics: US clinical-stage biotech developing ISAC (Immune-Stimulating Antibody Conjugate) platform combining linker-payload technology with immune agonism. Comparable as a differentiated ADC platform company with proprietary linker chemistry for targeted oncology therapeutics.

Broad incumbents

  • Daiichi Sankyo: Global pharmaceutical leader whose DXd platform underpins ENHERTU and a deep ADC pipeline. IntoCell's Nexatecans are explicitly positioned as DXd alternatives, making Daiichi Sankyo the benchmark incumbent for ADC linker-payload technology.

Direct peers

  • Heidelberg Pharma: German biopharma developing proprietary ADC platform (ATAC technology) with proprietary linker chemistry and payloads (amanitin). Direct competitor in the differentiated ADC linker-payload space, also pursuing out-licensing to biopharma partners.
  • Mersana Therapeutics: US clinical-stage biotech developing differentiated ADC platforms (Dolasynthen, Immunosynthen) with novel linker-payload systems. Directly comparable as an ADC platform company pursuing licensing and co-development deals with biopharma partners.
  • Tubulis: German biotech developing proprietary ADC linker and payload technologies (P5 conjugation, Tub-tag) for therapeutic applications. Direct peer as an ADC platform company focused on linker chemistry innovation and licensing.
  • LegoChem Biosciences: KOSDAQ-listed Korean ADC platform company where IntoCell's founder Tae-Kyo Park was previously co-founder and CTO. Both develop proprietary ADC linker-payload technologies for out-licensing and co-development, making them the most directly comparable peer in geography, business model, and technology focus.

Others

  • WuXi XDC: Hong Kong-listed global CRDMO focused on ADCs and bioconjugates, and a IntoCell partner (Jan 2024). Listed here as a strategic enabler/distributor that integrates IntoCell's drug-linker technology into its service platform, rather than a direct technology competitor.

Regional players

  • GeneQuantum Healthcare: China-based biotech developing site-specific ADC conjugation technologies and proprietary payloads for global biopharma partners. Comparable as an Asia-based ADC linker-payload platform company, with geographic overlap in APAC rather than direct global head-to-head competition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Intocell social profiles

Digital presence

Intocell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Intocell leadership team

Management profile

Number of profiles

Profiles9 records

Intocell funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Intocell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intocell

What does Intocell do?

Intocell develops and licenses proprietary Antibody-Drug Conjugate (ADC) linker-payload platform technologies—centered on the OHPAS™ linker, PMT™ payload modification technology, and Nexatecans™ camptothecin payloads—offered to pharmaceutical and biotech partners on a non-exclusive basis with upfront fees, milestones, and royalties. The company also advances a proprietary pipeline of ADC candidates (lead asset ITC-6146RO targeting B7-H3) and collaborates with CRDMO partners to integrate its drug-linker technologies into end-to-end ADC development services.

Is Intocell a public or private company?

Intocell is a public company. It is classified as public and is currently operating.

When was Intocell founded?

Intocell was founded in 2015. It employs 11 to 50 people.

Where is Intocell based?

Intocell is headquartered in Daejeon, South Korea, in the Asia region.

How does Intocell make money?

Two revenue lines are on record. Platform Technology Licensing (Non-exclusive) is the primary driver. The others are co-development and Research Collaboration.

Who are Intocell's main competitors?

Emerging players on record are Pyxis Oncology, ProfoundBio and Bolt Biotherapeutics. Daiichi Sankyo is listed as a broad incumbent. Direct peers are Heidelberg Pharma, Mersana Therapeutics, Tubulis and LegoChem Biosciences. WuXi XDC is listed as an others. GeneQuantum Healthcare is listed as a regional player.

Does Intocell have an API?

No public API is recorded for Intocell.

What industry is Intocell in?

Intocell's product category is ADC Platform Technology / Oncology Bioconjugates. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Naver포화된 넥틴-4 시장, 삼성에피스의 승부수는 '안정성'Samsung Biologics has expanded its clinical trial sites for SBE303, a Nectin-4 targeted ADC candidate, to six locations across the US, Australia, and Spain. The company is differentiating its product from competitors like Astellas and Pfizer by emphasizing superior safety profiles, citing monkey studies showing a 13x higher tolerated dose than key rivals. To support this stability, Samsung Biologics secured commercial rights to IntuCell's linker technology through a main contract.MoomooSamsung EpiS Unit Signs Cancer Drug Development, Commercialization Deal With IntoCellSamsung's Epis Holdings unit has signed a cancer drug development and commercialization agreement with IntoCell, as indicated by the article title and accompanying stock ticker data showing Epis Holdings Co shares rising 2.24% while IntoCell fell 15.60%. The article content is extremely limited due to scraped web artifacts and boilerplate, providing no additional details about the deal terms, timeline, or specific therapeutic approach involved.BusinesskoreaSamsung Bioepis Partners with IntoCell for Antibody-Drug Conjugate (ADC) CandidateSamsung Bioepis has entered into a commercial license agreement with IntoCell for exclusive rights to SBE303, an antibody-drug conjugate candidate targeting Nectin-4 that is jointly under development. The candidate, Samsung Bioepis' first novel ADC, is currently in Phase 1 clinical trials for advanced refractory solid tumors including urothelial, lung, and breast cancer. The agreement marks Samsung Bioepis' expansion beyond biosimilars into the oncology space, with financial terms remaining confidential.The Pharma LetterSamsung Bioepis enters ADC license accord with IntoCellSamsung Bioepis entered a commercial license agreement with IntoCell for SBE303, an antibody-drug conjugate candidate. The companies have collaborated since December 2023 to develop up to five ADC candidates using IntoCell's linker-payload technology.BiobuzzXcellon Biologics Builds Momentum With Multiple New ADC PartnershipsXcellon Biologics, a Maryland-based antibody-drug conjugate (ADC) contract development and manufacturing organization, announced two significant partnerships within a month—one with Wisconsin-based Invenra for multispecific ADC development and another with South Korea-based IntoCell for linker-payload technology integration. The company officially launched in January 2025, secured its first client within two weeks, and within its first year was supporting 14 programs including multiple repeat clients, with a new Maryland GMP facility expected to come online in 2026.GlobeNewswireIntoCell and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC TechnologiesIntoCell Inc., a South Korean biotechnology company, and Xcellon Biologics, a Maryland-based contract development and manufacturing organization, announced a strategic collaboration to advance antibody-drug conjugate (ADC) development and manufacturing. Under the agreement, IntoCell's proprietary OHPAS drug-linker platform, including Duocarmycin and Nexatecan-based payloads, will be integrated into Xcellon's ADC development toolbox, with Xcellon providing bioconjugation and manufacturing services to support clients using IntoCell's technologies. The partnership aims to accelerate access to innovative ADC technologies by combining IntoCell's chemistry platform with Xcellon's U.S.-based CDMO infrastructure.PR NewswirePiramal Pharma Solutions formalisiert Partnerschaft mit IntoCell und erweitert seine Payload-Linker-Plattform und Biokonjugat-KapazitätenPiramal Pharma Solutions, a global contract development and manufacturing organization (CDMO), signed a memorandum of understanding with South Korean biotech company IntoCell Inc. to strengthen their strategic partnership and explore antibody-drug conjugate (ADC) development opportunities. IntoCell brings proprietary drug-linker technologies and two decades of ADC development and manufacturing experience to the non-exclusive, non-binding agreement. The partnership is designed to support Piramal's rapid ADCelerate™ development and manufacturing approach, with IntoCell licensing its linker technologies to Piramal's customers while Piramal provides contract research, development, and manufacturing services for bioconjugates to IntoCell and its customer base.PR NewswirePiramal Pharma Solutions officialise son partenariat avec IntoCell, élargissant ainsi sa plateforme de payload-linker et ses capacités en matière de bioconjuguésPiramal Pharma Solutions has entered into a licensing partnership with IntoCell Inc. to expand its payload-linker platform and bioconjugate capabilities, integrating IntoCell's proprietary drug-linker technologies including the OHPAS linker, OHPAS duocarmycin-based payload, OHPAS Nexatecan-based payload, and GGFG iso-Nexatecan-based payload into its ADCelerate™ offering. The collaboration enables Piramal to offer a broader range of payload-linkers and shorter bioconjugate development timelines, strengthening its competitiveness in the ADC (antibody-drug conjugate) CDMO space. IntoCell CEO Tae Kyo Park and Piramal Global Pharma CEO Peter DeYoung both highlighted the strategic fit of combining their respective expertise in linker-payload technologies and bioconjugate development.PR NewswirePharmaVentures advises IntoCell on Development and License Option Agreement with ADC TherapeuticsPharmaVentures acted as exclusive advisor to South Korean biotech IntoCell on a Material Transfer Agreement with ADC Therapeutics for the license option of its antibody drug conjugate technologies. Under the agreement, IntoCell will provide proprietary drug-linkers and payload modification technology for ADC Therapeutics to conjugate with its antibodies for further development and testing.PR NewswireIntoCell Enters into Development and License Option Agreement with ADC TherapeuticsIntoCell, a South Korean biotech company, announced the signing of a Material Transfer Agreement with option to license with ADC Therapeutics, a commercial-stage biotechnology company. Under the agreement, IntoCell will provide its proprietary drug-linker technologies (OHPAS system and Payload Modification Technology) for ADC Therapeutics to conjugate with their antibodies and conduct in vitro, in vivo, and toxicology experiments. Upon successful evaluation, ADC Therapeutics will have the option to license the technology for up to six targets for global development and commercialization, with IntoCell entitled to receive signing fees, target selection fees, development milestones, and royalties.